Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 2
Submit an article Journal homepage
566
Views
67
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia

Clive S. ZentDivision of Hematology, Mayo Clinic, Rochester, MN, USACorrespondence[email protected]
,
Brian J. SmithDepartment of Biostatistics, Iowa City, IA, USA;Holden Comprehensive Cancer Center, Iowa City, IA, USA
,
Zuhair K. BallasHolden Comprehensive Cancer Center, Iowa City, IA, USA;Iowa City VA Medical Center, Iowa City, IA, USA
,
James E. WooldridgeHolden Comprehensive Cancer Center, Iowa City, IA, USA;Department of Internal Medicine, University of Iowa, Iowa City, IA, USA
,
Brian K. LinkHolden Comprehensive Cancer Center, Iowa City, IA, USA;Department of Internal Medicine, University of Iowa, Iowa City, IA, USA
,
Timothy G. CallDivision of Hematology, Mayo Clinic, Rochester, MN, USA
,
Tait D. ShanafeltDivision of Hematology, Mayo Clinic, Rochester, MN, USA
,
Deborah A. BowenDivision of Hematology, Mayo Clinic, Rochester, MN, USA
,
Neil E. KayDivision of Hematology, Mayo Clinic, Rochester, MN, USA
,
Thomas E. WitzigDivision of Hematology, Mayo Clinic, Rochester, MN, USA
&
George J. WeinerHolden Comprehensive Cancer Center, Iowa City, IA, USA;Department of Internal Medicine, University of Iowa, Iowa City, IA, USA
 show all
Pages 211-217 | Received 14 Jun 2011, Accepted 21 Jun 2011, Published online: 19 Sep 2011

References

  • Jemal A, Siegel R, Xu J, . Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
  • Zent CS, Kay NE. Management of chronic lymphocytic leukemia patients with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma 2011;52:1425–1434.
  • Sorror ML, Storer BE, Sandmaier BM, . Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26:4912–4920.
  • Dreger P, Dohner H, Ritgen M, . Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;116:2438–2447.
  • Spaner DE, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 2007;21:53–60.
  • Zent CS. Cell-mediated immunity in chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:1775–1776.
  • Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184–1194.
  • Jahrsdorfer B, Muhlenhoff L, Blackwell SE, . B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005;11:1490–1499.
  • Decker T, Schneller F, Sparwasser T, . Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999–1006.
  • Kim YH, Girardi M, Duvic M, . Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010;63: 975–983.
  • Jahrsdorfer B, Wooldridge JE, Blackwell SE, . Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005;77:378–387.
  • Liang X, Moseman EA, Farrar MA, . Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 2010;115:5041–5052.
  • Krieg AM, Efler SM, Wittpoth M, . Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004;27: 460–471.
  • Yamada K, Nakao M, Fukuyama C, . Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Sci 2010;101:188–195.
  • Manegold C, Gravenor D, Woytowitz D, . Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26: 3979–3986.
  • Link BK, Ballas ZK, Weisdorf D, . Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 2006;29:558–568.
  • Leonard JP, Link BK, Emmanouilides C, . Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007;13:6168–6174.
  • Cheson BD, Bennett JM, Grever M, . National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.